Posted On: 03/02/2015 5:15:50 PM
Post# of 30067
Barcode,
My theory is that the spike in volume has something to do with Roche receiving that COPD patent last week (Feb. 26). I'm not a lawyer. But after reading both patents you referenced, it sounds like Roche will need to pay AMBS for every ARMET (MANF) test used to check for various cancers and COPD.
Each patent is basically saying that the naturally-occurring MANF content of a patient's sample (e.g. blood sample) would be measured against a "control concentration" of MANF. Based on the context, it sounded like the "control concentration" of MANF was a non-naturally occurring form of MANF (i.e. recombinant MANF).
What's your interpretation of the patents?
My theory is that the spike in volume has something to do with Roche receiving that COPD patent last week (Feb. 26). I'm not a lawyer. But after reading both patents you referenced, it sounds like Roche will need to pay AMBS for every ARMET (MANF) test used to check for various cancers and COPD.
Each patent is basically saying that the naturally-occurring MANF content of a patient's sample (e.g. blood sample) would be measured against a "control concentration" of MANF. Based on the context, it sounded like the "control concentration" of MANF was a non-naturally occurring form of MANF (i.e. recombinant MANF).
What's your interpretation of the patents?
(0)
(0)
